Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Kisspeptin for Women 45-55 Perimenopause: Protocol Comparison

Researchers and clinicians exploring kisspeptin protocols for perimenopausal symptom management need to understand how different dosing strategies, peptide isoforms, and administration frequencies produce distinct hormonal and symptomatic outcomes. Acute LH Su

This comparison does not assign a generated winner or score.

  • Researchers and clinicians exploring kisspeptin protocols for perimenopausal symptom management need to understand how different dosing strategies, peptide isoforms, and administration frequencies produce distinct hormonal and symptomatic outcomes.
  • Acute LH Surge Induction (Fertility Research)
  • Kisspeptin-54
  • 6.4–12.8 nmol/kg
  • Single bolus injection
  • Triggers immediate LH surge within 2–4 hours, mimicking natural ovulatory peak
  • Unsuitable for perimenopause. Causes exaggerated LH spike, worsening hot flashes
  • Not applicable to symptom management; designed for ovulation triggering in controlled cycles
  • Sustained Pulse Coordination (Symptom Management)
  • Kisspeptin-10
  • 3.2–6.4 nmol/kg
  • Twice daily (BID), 12-hour intervals
  • Normalizes LH pulse frequency, reduces amplitude variability by 30–40%
  • 40% hot flash reduction by week 4; sleep quality improvement noted by week 2
  • Gold standard for perimenopausal vasomotor symptom trials; balances efficacy with practical twice-daily schedule
  • Low-Dose Maintenance (Exploratory)
  • 1.6–3.2 nmol/kg
  • Once daily (QD)
  • Partial LH modulation; symptom reduction less consistent than BID protocols
  • Modest improvement (15–25% hot flash reduction); adequate for mild symptoms only
  • Untested in published trials; theoretical benefit for women with subclinical symptoms or as step-down from BID therapy
  • Continuous Infusion (Research Setting)
  • 0.01–0.1 nmol/kg/min
  • IV infusion over 8–24 hours
  • Steady-state GnRH stimulation; eliminates pulsatile variation entirely
  • Near-complete hot flash suppression during infusion; symptoms return within 6 hours post-discontinuation
  • Proof-of-concept only; impractical for clinical use but validates mechanism; demonstrates kisspeptin's short half-life necessitates frequent dosing
  • The comparison underscores a critical reality: kisspeptin's therapeutic window for perimenopause requires sustained, pulsatile dosing that mimics endogenous GnRH rhythm restoration. Not acute surges. Single daily doses or erratic administration fail to maintain the coordinated pulse pattern necessary for symptom control.